NCT06383780 2024-07-16
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
3 trialsNCT05211232 2024-04-18
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting